Startups
Arbele, a biopharmaceutical company based in the US and HK to develop first-in-class antibody-based immunotherapeutic products to cure cancers
Overview
Location
United States
Employees
11-50
Phone
+852 3620 3002
Founded date
2016
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 2, 2025 | Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition | BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies a... |
| Oct 9, 2024 | Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics | SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial inte... |
| Apr 26, 2024 | Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers | The second DMC review recommends the continuation of dose escalation in the clinical trial as per protocol. The interim safety assessment was based on the review of safety data from 18 metastatic gastrointestinal cancer patients, including ... |
| Aug 3, 2023 | Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting | SYDNEY, Aug. 3, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-... |
| May 5, 2023 | Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary | SEATTLE, May 5, 2023 /PRNewswire/ -- Arbele, a biotechnology company dedicated to fighting gastrointestinal cancers, celebrates its 7th anniversary and the opening of Tiberias Technology (TibTech), its accredited lab for cancer screening an... |
| Aug 10, 2022 | Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers | SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers ... |
| Apr 7, 2021 | Asian Fund for Cancer Research Announces Inaugural BRACE Award Venture Competition Winner | Gastrointestinal Cancer Drug Developer Arbele Receives AFCR Investment Funding HONG KONG SAR – Media OutReach – 8 April 2021 – Arbele has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) inaugural BRACE Award Ventu... |
Reviews 0
FAQ about Arbele
When was Arbele founded?
Arbele was founded in 2016.
What has the press written about Arbele?
Parsers VC has collected 8 articles mentioning Arbele, among them “Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition” (Jul 2, 2025) and “Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics” (Oct 9, 2024).
Is Arbele still active?
Yes, Arbele is active; its latest activity on Parsers VC dates from Jan 8, 2026.